Tripill Biotech

Tripill Biotechnology is a pioneering radiopharmaceutical startup spun off from the University of North Carolina at Chapel Hill (UNC-Chapel Hill). Incorporated in November 2022, the company specializes in the development of targeted radionuclide therapeutic (TRT) agents for cancer treatment. At the core of Tripill's innovation is its proprietary linker technology platforms, including a cyanuric acid-derived tri-vinyl sulfone (CA-TVS) core, which enables the rapid, high-yield assembly of multifunctional and multitargeting radiotheranostic agents. The company's lead programs include a radiolabeled prostate-specific membrane antigen (PSMA) agent designed to selectively reduce salivary gland toxicity (a common dose-limiting side effect of PSMA therapies) and astatine-211-labeled agents for melanoma management.